Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 3/20 | 0.33 |
| ▸ | ABL1 | P00519 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.32 |
| ▸ | MAP4K1 | Q92918 | 3/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.31 |
| ▸ | PDE9A | O76083 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6100142 | 0.90 | CHRNA7 (0.32) | USP30CHRNA7KDM4ENPC1ALDH1A1 | |
| SCHEMBL6099240 | 0.85 | KDM4E (0.34) | GRM5ABL1CHRNA7KDM4ENPC1 | |
| SCHEMBL6101004 | 0.85 | CHRNB2 (0.34) | GRM5CHRNA7KDM4ENPC1ALDH1A1 | |
| SCHEMBL6101341 | 0.83 | IRAK4 (0.36) | USP30GRM5ABL1HTTCHRNA7 | |
| SCHEMBL6099257 | 0.83 | GRM5 (0.36) | GRM5ARNPC1RAB9A | |
| SCHEMBL6098642 | 0.82 | HCRTR1 (0.37) | CHRNA7KDM4ENPC1ALDH1A1MAPT | |
| SCHEMBL6100564 | 0.82 | KDM1A (0.37) | USP30GRM5ABL1HTTCHRNA7 | |
| SCHEMBL6100286 | 0.81 | GRM5 (0.36) | GRM5ARNPC1ALDH1A1LMNA | |
| SCHEMBL843629 | 0.80 | CHRNA7 (0.35) | CHRNA7PDE9A | |
| SCHEMBL6100073 | 0.80 | USP30 (0.37) | USP30GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1478646-A1 | AZABICYCLIC COMPOUNDS WITH ALFA7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | PHARMACIA & UPJOHN COMPANY (US) | 2004-11-24 | — | — | EP | claimed |
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | claimed |
| WO-2003072578-A1 | AZABICYCLIC COMPOUNDS WITH ALFA7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | PHARMACIA & UPJOHN COMPANY (US) | 2003-09-04 | — | — | WO | claimed |
| US-7001900-B2 | Azabicyclic compounds for the treatment of disease | PFIZER INC. (US) | 2006-02-21 | — | — | US | disclosed |
| EP-1478646-A1 | AZABICYCLIC COMPOUNDS WITH ALFA7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | PHARMACIA & UPJOHN COMPANY (US) | 2004-11-24 | — | — | EP | disclosed |
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | disclosed |
| WO-2003072578-A1 | AZABICYCLIC COMPOUNDS WITH ALFA7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | PHARMACIA & UPJOHN COMPANY (US) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | MALT1, TPMT, CYP2B6 | USP30 3403/4885GRM5 1965/4885ABL1 236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.